MedTrace Logo

Autologous Plasma Rich in Growth Factors for Severe Dry Eye Disease

NCT07773740 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-08-25

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the change in dry eye symptoms after the treatment with Plasma Rich in Growth Factors (PRGF) in patients with severe dry eye. The main question it aims to answer is:

Are dry eye simptoms less after the treatment with PRGF?

Researchers will compare standard topical treatment and PRGF with standard topical treatment and placebo to see if there is a difference in dry eye symptoms between arms. Secondary outcomes include changes in tear meniscus height, non invasive tear break-up time, conjunctival hyperemia, meibomian gland dropout and Ocular Staining Score (OSS) scale for corneal and conjunctival damage.

Participants will be asked to use standard treatment and PRGF or placebo for 1 month.

Conditions

  • Dry Eye Disease With Severe Keratitis

Interventions

OTHER

PRGF

PRGF eyedrops four times a day for 1 month

OTHER

Balanced Salt Solution (BSS®)

Balanced salt solution 0.09% eyedrops four times a day for 1 month

Sponsors & Collaborators

  • Lansier

    collaborator UNKNOWN

  • Gladys Lucia Silva Linares

    lead OTHER

Principal Investigators

  • Kieran S. O´brien, MD · Seva Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-25
Primary Completion
2027-08-31
Completion
2027-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07773740 on ClinicalTrials.gov